Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CA102N + trifluridine/tipiracil hydrochloride|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CA102N||CA 102N|CA-102N|Nim-HA Conjugate|HA-Nimesulide||CA102N is composed of sodium hyaluronate (NaHA) in conjugation with the COX-2 inhibitor nimesulide, which may target the HA receptor CD44-expressing tumor cells for growth inhibition (Cancer Res 2015;75(15 Suppl):Abstract nr 4471, PMID: 28392690).|
|trifluridine/tipiracil hydrochloride||Lonsurf||TAS-102||Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth and is FDA approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03616574||Phase I||CA102N CA102N + trifluridine/tipiracil hydrochloride||First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors||Recruiting|